{"id":"https://openalex.org/W3201242536","doi":"https://doi.org/10.1111/dom.14553","title":"The dual glucose\u2010dependent insulinotropic polypeptide and glucagon\u2010like peptide\u20101 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A p ost hoc analysis","display_name":"The dual glucose\u2010dependent insulinotropic polypeptide and glucagon\u2010like peptide\u20101 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A p ost hoc analysis","publication_year":2021,"publication_date":"2021-09-20","ids":{"openalex":"https://openalex.org/W3201242536","doi":"https://doi.org/10.1111/dom.14553","mag":"3201242536","pmid":"https://pubmed.ncbi.nlm.nih.gov/34542221","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/9292792"},"language":"en","primary_location":{"id":"doi:10.1111/dom.14553","doi":"https://doi.org/10.1111/dom.14553","is_oa":true,"landing_page_url":"https://doi.org/10.1111/dom.14553","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1111/dom.14553","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5003206993","display_name":"Jonathan Matthew Wilson","orcid":"https://orcid.org/0000-0002-8648-600X","observed_orcids":["https://orcid.org/0000-0002-8648-600X"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan M. Wilson","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113120326","display_name":"Yanzhu Lin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yanzhu Lin","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":null,"display_name":"M. Jane Luo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Jane Luo","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038117470","display_name":"Gary Considine","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gary Considine","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068319406","display_name":"Amy L. Cox","orcid":"https://orcid.org/0009-0008-1571-6016","observed_orcids":["https://orcid.org/0009-0008-1571-6016"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy L. Cox","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056809399","display_name":"Lenden M. Bowsman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lenden M. Bowsman","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081732583","display_name":"Deborah A. Robins","orcid":"https://orcid.org/0000-0001-9694-7319","observed_orcids":["https://orcid.org/0000-0001-9694-7319"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Deborah A. Robins","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":"https://orcid.org/0000-0001-9694-7319","affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040811419","display_name":"Axel Haupt","orcid":"https://orcid.org/0000-0003-4502-0470","observed_orcids":["https://orcid.org/0000-0003-4502-0470"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Axel Haupt","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":"https://orcid.org/0000-0003-4502-0470","affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072130761","display_name":"Kevin L. Duffin","orcid":"https://orcid.org/0000-0002-1656-8982","observed_orcids":["https://orcid.org/0000-0002-1656-8982"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin L. Duffin","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5078824497","display_name":"Giacomo Ruotolo","orcid":"https://orcid.org/0000-0001-5247-5444","observed_orcids":["https://orcid.org/0000-0001-5247-5444"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Giacomo Ruotolo","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":"https://orcid.org/0000-0001-5247-5444","affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5078824497"],"corresponding_institution_ids":["https://openalex.org/I168537998"],"apc_list":{"value":4700,"currency":"USD","value_usd":4700},"apc_paid":{"value":4700,"currency":"USD","value_usd":4700},"fwci":14.1688,"has_fulltext":false,"cited_by_count":149,"citation_normalized_percentile":{"value":0.99498775,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":100},"biblio":{"volume":"24","issue":"1","first_page":"148","last_page":"153"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10528","display_name":"Adipokines, Inflammation, and Metabolic Diseases","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tirzepatide","display_name":"tirzepatide","score":1.0},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9240000247955322},{"id":"https://openalex.org/keywords/cardiovascular-risk-markers","display_name":"cardiovascular risk markers","score":0.8500000238418579},{"id":"https://openalex.org/keywords/gip-glp-1-receptor-agonist","display_name":"GIP/GLP-1 receptor agonist","score":0.8309999704360962},{"id":"https://openalex.org/keywords/dulaglutide","display_name":"dulaglutide","score":0.9509999752044678},{"id":"https://openalex.org/keywords/ykl-40","display_name":"YKL-40","score":0.8640000224113464},{"id":"https://openalex.org/keywords/icam-1","display_name":"ICAM-1","score":0.9710000157356262},{"id":"https://openalex.org/keywords/leptin","display_name":"leptin","score":0.9890000224113464},{"id":"https://openalex.org/keywords/high-sensitivity-c-reactive-protein","display_name":"high-sensitivity C-reactive protein","score":0.9639999866485596},{"id":"https://openalex.org/keywords/inflammation","display_name":"inflammation","score":0.9020000100135803},{"id":"https://openalex.org/keywords/endothelial-dysfunction","display_name":"endothelial dysfunction","score":0.9980000257492065},{"id":"https://openalex.org/keywords/glyca","display_name":"GlycA","score":0.5339999794960022},{"id":"https://openalex.org/keywords/interleukin-6","display_name":"interleukin-6","score":0.925000011920929},{"id":"https://openalex.org/keywords/n-terminal-probnp","display_name":"N-terminal proBNP","score":0.6600000262260437},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.5429999828338623},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.7710000276565552}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8234913349151611},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.8007122278213501},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.7206454277038574},{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.6343756318092346},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5365410447120667},{"id":"https://openalex.org/C185280430","wikidata":"https://www.wikidata.org/wiki/Q14909910","display_name":"Glucagon-like peptide 1 receptor","level":4,"score":0.530523419380188},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5304642915725708},{"id":"https://openalex.org/C2779829264","wikidata":"https://www.wikidata.org/wiki/Q21011228","display_name":"Dulaglutide","level":5,"score":0.526201069355011},{"id":"https://openalex.org/C2780613262","wikidata":"https://www.wikidata.org/wiki/Q223739","display_name":"Leptin","level":3,"score":0.4959932267665863},{"id":"https://openalex.org/C2775915353","wikidata":"https://www.wikidata.org/wiki/Q1571529","display_name":"Natriuretic peptide","level":3,"score":0.44321373105049133},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.4431600570678711},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.4230487644672394},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.28328973054885864},{"id":"https://openalex.org/C2778198053","wikidata":"https://www.wikidata.org/wiki/Q181754","display_name":"Heart failure","level":2,"score":0.12580305337905884},{"id":"https://openalex.org/C511355011","wikidata":"https://www.wikidata.org/wiki/Q12174","display_name":"Obesity","level":2,"score":0.08270785212516785},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000082742","descriptor_name":"Heart Disease Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000097789","descriptor_name":"Glucagon-Like Peptide-1 Receptor Agonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000098860","descriptor_name":"Tirzepatide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D005749","descriptor_name":"Gastric Inhibitory Polypeptide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D007141","descriptor_name":"Immunoglobulin Fc Fragments","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015415","descriptor_name":"Biomarkers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1111/dom.14553","doi":"https://doi.org/10.1111/dom.14553","is_oa":true,"landing_page_url":"https://doi.org/10.1111/dom.14553","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:9292792","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9292792","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Obes Metab","raw_type":"Text"},{"id":"pmid:34542221","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/34542221","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":{"id":"doi:10.1111/dom.14553","doi":"https://doi.org/10.1111/dom.14553","is_oa":true,"landing_page_url":"https://doi.org/10.1111/dom.14553","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8100000023841858}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":18,"referenced_works":["https://openalex.org/W244067736","https://openalex.org/W1671590615","https://openalex.org/W1812416290","https://openalex.org/W2317095451","https://openalex.org/W2412937130","https://openalex.org/W2890783608","https://openalex.org/W2895666357","https://openalex.org/W2900446046","https://openalex.org/W2968073288","https://openalex.org/W2985692253","https://openalex.org/W3008317004","https://openalex.org/W3049084794","https://openalex.org/W3049167578","https://openalex.org/W3086455642","https://openalex.org/W3147549241","https://openalex.org/W3155824129","https://openalex.org/W3201242536","https://openalex.org/W3204118678"],"related_works":["https://openalex.org/W3103007714","https://openalex.org/W7163352959","https://openalex.org/W4406049606","https://openalex.org/W7220693644","https://openalex.org/W7161835230","https://openalex.org/W4387022758","https://openalex.org/W3049084794","https://openalex.org/W7171511742","https://openalex.org/W4200062587","https://openalex.org/W4414689177"],"abstract_inverted_index":{"In":[0,42,192],"a":[1],"phase":[2],"2":[3,40],"trial":[4],"of":[5,68,168],"once-weekly":[6],"tirzepatide":[7,29,69,77,171,197],"(1,":[8],"5,":[9],"10,":[10],"or":[11,17],"15":[12,80,99,113,174],"mg),":[13,16],"dulaglutide":[14],"(1.5":[15],"placebo,":[18,132],"the":[19,65,177],"dual":[20],"glucose-dependent":[21],"insulinotropic":[22],"polypeptide":[23],"and":[24,33,50,60,79,95,103,105,110,121,123,131,144,160,173,185],"glucagon-like":[25],"peptide-1":[26],"receptor":[27],"agonist":[28],"dose-dependently":[30],"reduced":[31],"HbA1c":[32],"body":[34],"weight":[35],"in":[36,155,179],"patients":[37],"with":[38,170,205],"type":[39],"diabetes.":[41],"this":[43,193],"post":[44],"hoc":[45],"analysis,":[46,196],"inflammation,":[47],"endothelial":[48],"dysfunction,":[49],"cellular":[51],"stress":[52],"biomarkers":[53,200],"were":[54,151],"measured":[55],"at":[56],"baseline,":[57,102],"4,":[58],"12,":[59],"26":[61,75,190],"weeks":[62,167],"to":[63],"evaluate":[64],"additional":[66],"effects":[67],"on":[70],"cardiovascular":[71,206],"risk":[72],"factors.":[73],"At":[74],"weeks,":[76],"10":[78,172],"mg":[81,114],"decreased":[82,116,164,198],"YKL-40":[83,104],"(also":[84],"known":[85],"as":[86],"chitinase-3":[87],"like-protein-1),":[88],"intercellular":[89],"adhesion":[90,141],"molecule":[91,142],"1":[92],"(ICAM-1),":[93],"leptin,":[94],"growth":[96],"differentiation":[97],"factor":[98],"levels":[100,107,118,128,150,162,181],"versus":[101,108,119,129],"leptin":[106,180],"placebo":[109,120],"dulaglutide.":[111,135],"Tirzepatide":[112],"also":[115],"ICAM-1":[117,161],"dulaglutide,":[122],"high-sensitivity":[124],"C-reactive":[125],"protein":[126],"(hsCRP)":[127],"baseline":[130],"but":[133],"not":[134,152,187],"GlycA,":[136],"interleukin":[137],"6,":[138],"vascular":[139],"cell":[140],"1,":[143],"N-terminal-pro":[145],"hormone":[146],"B-type":[147],"natriuretic":[148],"peptide":[149],"significantly":[153],"changed":[154],"any":[156],"group.":[157],"YKL-40,":[158],"hsCRP,":[159],"rapidly":[163],"within":[165],"4":[166],"treatment":[169],"mg,":[175],"whereas":[176],"decrease":[178],"was":[182],"more":[183],"gradual":[184],"did":[186],"plateau":[188],"by":[189],"weeks.":[191],"hypothesis-generating":[194],"exploratory":[195],"several":[199],"that":[201],"have":[202],"been":[203],"associated":[204],"risk.":[207]},"counts_by_year":[{"year":2026,"cited_by_count":38},{"year":2025,"cited_by_count":35},{"year":2024,"cited_by_count":31},{"year":2023,"cited_by_count":24},{"year":2022,"cited_by_count":19},{"year":2021,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2021-09-27T00:00:00"}